Construction Partners (NASDAQ: ROAD) has emerged as a standout cash-producing investment, posting a trailing 12-month free cash flow margin of 6.7% alongside exceptional revenue momentum.
Founded in 2001, Construction Partners is a civil infrastructure company that builds and maintains roads, highways, and other infrastructure projects across the United States.
The company’s annual revenue growth of 39.9% over the last two years signals strong market share gains during a highly competitive cycle for civil infrastructure.
Earnings per share growth of 46.7% over the same two-year period outstripped even its impressive revenue performance, reflecting strong operating leverage as sales scaled.
Construction Partners also expanded its free cash flow margin by 7.4 percentage points over the last five years, giving management significantly more financial flexibility to pursue growth.
At $123.14 per share, the stock currently trades at 39.8x forward price-to-earnings, a premium that appears increasingly justified given the company’s consistent execution and infrastructure tailwinds.
On the other side of the ledger, Raytheon (NYSE: RTX), the aerospace and defense giant originally rooted in refrigeration technology, presents a less compelling investment case despite generating a 9.4% free cash flow margin.
Estimated sales growth of just 5.9% for the next 12 months implies a deceleration from RTX’s two-year trend, raising questions about whether the company can maintain its current pace.
A return on capital of just 4.7% further reflects management’s difficulties in identifying and executing on profitable growth opportunities within its sprawling defense and aerospace portfolio.
With RTX shares priced at $185.63 and trading at 26.3x forward price-to-earnings, the valuation does not appear compelling enough to offset the underlying concerns around growth and capital allocation.
West Pharmaceutical Services (NYSE: WST), a pharmaceutical packaging and drug delivery manufacturer founded in 1923, also raises red flags for investors despite a solid 14.2% free cash flow margin.
The company’s annual revenue growth of just 4.9% over the last two years fell below the typical growth rate seen across the broader healthcare sector, suggesting limited competitive differentiation.
Adjusted operating margin fell by 5.8 percentage points over the last five years, pointing to rising day-to-day expenses that have grown faster than revenue and pressured profitability.
Shrinking returns on capital at West Pharmaceutical Services further suggest that intensifying competition is steadily eroding the company’s once-reliable profit generation.
WST currently trades at $336.34 per share at a forward price-to-earnings multiple of 37.8x, a lofty valuation that looks difficult to justify given the margin deterioration and slowing growth trajectory.
Generating cash is a fundamental requirement for any healthy business, but the ability to allocate that cash toward profitable opportunities is ultimately what separates good investments from great ones.
Construction Partners continues to demonstrate precisely that combination, making it the clear standout among the three companies examined for investors seeking quality infrastructure exposure in 2026.
